Kaname Miyamoto
Eisai
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kaname Miyamoto.
Gastroenterology | 1990
Junichi Nagakawa; Ieharu Hishinuma; Kazuo Hirota; Kaname Miyamoto; Takashi Yamanaka; Kazuo Tsukidate; Kouichi Katayama; Isao Yamatsu
The possible involvement of tumor necrosis factor-alpha in the pathogenesis of an experimentally induced hepatitis was investigated. Balb/c mice were primed with Propionibacterium acnes to induce the infiltration of mononuclear cells into the liver. Immunohistochemical study showed that most of the accumulated mononuclear cells at 7 days were Mac-2 positive, suggesting that they were activated macrophages. An injection of lipopolysaccharide resulted in massive hepatic necrosis and high mortality in the mice within 24 hours. Plasma tumor necrosis factor-alpha activity initially rose sharply and then declined over 3 hours. The increase in plasma aminotransferase activity correlated well with the elevation of plasma tumor necrosis factor-alpha activity. Pretreatment with dexamethasone or 16,16-dimethyl-prostaglandin E2 attenuated not only the elevation of plasma tumor necrosis factor-alpha activity but also the increase in plasma aminotransferase activity and improved the survival rate. Passive immunization against tumor necrosis factor-alpha showed protective effects. These findings suggest that tumor necrosis factor-alpha released from activated macrophages may play a crucial role in the pathogenesis of this murine hepatitis.
Inflammation Research | 1992
Kaname Miyamoto; Junichi Nagakawa; Ieharu Hishinuma; Kazuo Hirota; M. Yasuda; Takashi Yamanaka; Kouichi Katayama; Isao Yamatsu
E3330 {(2E)-3-[5-(2,3-dimethoxy-6-methyl-1,4-benzoquinoyl)]-2-nonly-2-propenoic acid}, a novel synthesized hepatoprotective compound, has suppressive effects on tumor necrosis factor-α (TNF-α) generation from monocytes/macrophagesin vitro. E3330 (1–100 μM) reduced lipopolysaccharide (LPS, 10 mg/ml or 1μg/ml)-induced TNF-α generation from rat resident andPropionibacterium acnes (P. acnes)-elicited peritoneal macrophages, rat and human monocytes, rat Kupffer cells, and splenic mononuclear cells in a concentration-dependent manner. E3330 also (1–100 μM) suppressed TNF-α generation stimulated with egg-albumin immune complex in ratP. acnes-elicited peritoneal macrophages. Northern blot analysis showed that LPS-induced expression of TNF-α messenger RNA (mRNA) in human blood monocytes was suppressed by E3330. These findings indicate that E3330 has a suppressive effect on TNF-α generation from monocytes/macrophages, regardless of origin or species, and this effect is based in part on the suppression of TNF-α mRNA expression.
European Journal of Pharmacology | 1992
Junichi Nagakawa; Ieharu Hishinuma; Kazuo Hirota; Kaname Miyamoto; Takashi Yamanaka; Isao Yamatsu; Kouichi Katayama
Oral pretreatment with E3330, a novel quinone derivative, attenuated liver injury induced with tumor necrosis factor-alpha in galactosamine-sensitized mice. Tumor necrosis factor-alpha is known to induce inflammatory mediators such as leukotrienes and prostanoids. An in vitro study showed that E3330 inhibited the generation of leukotriene B4 and thromboxane B2, but enhanced prostaglandin E2 generation from rat peritoneal exudate cells stimulated with the Ca(2+)-ionophore, A23187. These findings suggest that the protective effect of E3330 on galactosamine/tumor necrosis factor-alpha hepatitis is due at least in part to its inhibition of the generation of leukotrienes. The inhibition of thromboxane B2 generation or the enhancement of prostaglandin E2 generation by E3330 may also contribute to its hepatoprotective effect.
Immunopharmacology and Immunotoxicology | 1991
Junichi Nagakawa; Ieharu Hishinuma; Kazuo Hirota; Kaname Miyamoto; M. Yasuda; Takashi Yamanaka; Kouichi Katayama
AbstractThe possible involvement of interleukin-lα (IL-lα) in the pathogenesis of murine hepatitis model induced with galactosamine and lipopolysaccharide (LPS) was investigated. the injection of 10 ng/mouse of LPS in combination with 10 mg/mouse of galactosamine into mice induced hepatic damage at 24 hours. Treatment with anti-mouse IL-1α antiserum 30 min before galactosamine/LPS injection showed a tendency to reduce the liver injury, while pretreatment with anti-mouse tumor necrosis factor-α (TNF) antiserum significantly protected mice from liver injury. the use of recombinant murine TNF, instead of LPS, in combination with galactosamine could elicit hepatic damage, whereas recombinant murine IL-lα could not substitute for LPS. However, recombinant murine IL-lα enhanced the hepatotoxic effect of recombinant murine TNF in galactosamine-sensitized mice. These results suggest that TNF plays a major role in the pathogenesis of galactosamine/LPS hepatitis in mice and that IL-lα acts synergistically with TNF ...
Hepatology | 1990
Ieharu Hishinuma; Junichi Nagakawa; Kazuo Hirota; Kaname Miyamoto; Kazuo Tsukidate; Takashi Yamanaka; Kouichi Katayama; Isao Yamatsu
Archive | 1990
Shinya Abe; Yasushi Okamoto; Katsuya Tagami; Shigeki Hibi; Junichi Nagakawa; Kazuo Hirota; Ieharu Hishinuma; Kaname Miyamoto; Takashi Yamanaka; Hiromitsu Yokohama; Tsutomu Yoshimura; Tohru Horie; Yasunori Akita; Koichi Katayama; Isao Yamatsu
Antimicrobial Agents and Chemotherapy | 1998
Seiichi Kobayashi; Tsutomu Kawata; Akifumi Kimura; Kaname Miyamoto; Koichi Katayama; Isao Yamatsu; Daniel P. Rossignol; William J. Christ; Yoshito Kishi
Folia Pharmacologica Japonica | 1988
Kaname Miyamoto; Ieharu Hishinuma; Junichi Nagakawa; Naoko Nagaoka; Takashi Yamanaka; Tsuneo Wakabayashi
Journal of Medicinal Chemistry | 1996
Shigeki Hibi; Yasushi Okamoto; Katsuya Tagami; Hirotoshi Numata; Naoki Kobayashi; Masanobu Shinoda; Tetsuya Kawahara; Koukichi Harada; Kaname Miyamoto; Isao Yamatsu
Archive | 1990
Shigeru Souda; Naoyuki Shimomura; Norihiro Ueda; Shuhei Miyazawa; Takashi Yamanaka; Kaname Miyamoto; Ieharu Hishinuma; Junichi Nagakawa; Naoko Nagaoka; Hidetoshi Kawashima; Tsutomu Kawata; Junsaku Nagaoka; Tsuneo Wakabayashi